Molecular aspects of azole antifungal action and resistance

Drug Resistance Updates

Volumn 2, Issue 6, 1999, Pages 390-402

  Lamb, David ^a   Kelly, Diane ^a   Kelly, Steven ^a  

^a ABERYSTWYTH UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; PYRROLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; DRUG STRUCTURE; FUNGAL GENETICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE;

EID: 0033502717     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0112     Document Type: Article

References (83)

1. Vanden Bossche H., Willlemsens G., Cools W., Marichal P., Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substitued imidazoles and triazoles. Biochem Soc Trans. 11:1993;665-667.
2. Mercer E. I. Morpholine antifungals and their mode of action. Biochem Soc Trans. 19:1991;788-793.
3. Mercer E. I. Inhibitors of sterol biosynthesis and their applications. Prog Lipid Res. 32:1993;357-416.
4. Sirtori C. R. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res. 22:1990;555-563.
5. Kelly S. L., Arnoldi A., Kelly D. E. Molecular genetic analysis of azole antifungal mode of action. Biochem Soc Trans. 21:1993;1034-1038.
6. Buchenauer H. Physiological reactions in the inhibition of plant pathogenic fungi. Haug G., Hoffman H. Chemistry of plant protection Vol. 6: controlled release, biochemical effects of peasticides and inhibition of plant pathogenic fugi. 1990;217-292 Springer-Verlag, Berlin.
7. Kelly S. L., Kelly D. E. Molecular studies on azole sensitivity in fungi. Maresca B., Kobayachi G., Yamaguchi H. Molecular Biology and its application to Medical Mycology. 1993;199-214 Springer-Verlag, Berlin.
8. Ragsdale N. H., Sisler H. D. Inhibition of ergosterol biosynthesis in Ustilago maydis by the fungicide triarimol. Biochem Biophys Res Commun. 46:1972;2048-2053.
9. Alexander K. T. W., Mitropoulos K. A., Gibbons G. F. A possible role for cytochrome P450 during the biosynthesis of zymosterol from lanosterol by S. cerevisiae. Biochem Biophys Res Commun. 60:1974;460-467.
10. Vanden Bossche H., Marichal P., Gorrens J., Bellens D., Moerells H., Janssen P. A.J. Interaction of azole derivatives with cytochrome P450 isozymes in yeast fungi plant and mammalian cells. Pestic Sci. 21:1987;306-309.
11. Wiggins T., Baldwin B. C. Binding of azole fungicides related to diclobutrazol to cytochrome P450. Pestic Sci. 15:1984;206-209.
12. Yoshida Y., Aoyama Y. Interaction of azole antifungal agents with cytochrome P45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol. 36:1987;229-235.
13. Hata S., Nishino T., Komori M., Katsuki H. Involvement of a cytochrome P450 in 22-desaturation desaturation in ergosterol biosynthesis of yeast. Biochem Biophys Res Commun. 103:1981;272-277.
14. Kelly S. L., Lamb D. C., Corran A. J., Baldwin B. C., Parks L. W., Kelly D. E. Purification and reconstitution of activity of Saccharomyces cerevisiae P 450 61, a sterol 22-desaturase. FEBS Lett. 377:1995;217-220.
15. Skaggs B. A., Alexander J. F., Pierson C. A. Cloning and characterisation of the Saccharomyces cerevisiae C-22 sterol desaturase gene, encoding a 2nd cytochrome P450 involved in ergosterol biosynthesis. Gene. 169:1996;105-109.
16. Kelly S. L., Lamb D. C., Corran A. J., Baldwin B. C., Kelly D. E. Characterisation of Saccharomyces cerevisiae CYP61; sterol 22-desaturase and inhibition by azole antifungals. J Biol Chem. 272:1997;9986-9988.
17. Kelly S. L., Lamb D. C., Kelly D. E. Sterol 22-desaturase, cytochrome P45061, possesses activity in xenobiotic metabolism. FEBS Lett. 412:1997;233-235.
18. Aoyama Y., Noshiro M., Gotoh O. Sterol 14-demethylase P450 (P45014DM) is one of the most ancient and conserved P450 species. J Biochem. 119:1996;926-933.
19. Jafcoate C. R., Gaylor J. L., Calabrese R. L. Ligand interactions with cytochrome P450. I. Binding of primary amines. Biochemistry. 8:1969;455-3463.
20. cam. J Mol Graph. 12:1994;185-193.
21. Graham S. E., Peterson J. A. How similar are P450s and what can their differences teach us? Arch Biochem Biophys. 369:1999;24-29.
22. 5,6-desaturase. FEBS Lett. 400:1997;80-82.
23. Watson, P. F. Rose, M. E. King, D. J. Ellis, S. W. England, H. Kelly, S. L. Defective sterol C5-6 desaturation and azole resistance: A new hypothesis on the mode of action of azole antifungals. Biochem Biophys Res Commun, 1989, 164, 1170, 1175.
24. Kelly S. L., Lamb D. C., Kelly D. E., Loeffle R. J., Einsele H. Resistance to fluconazole in Candida albicans from AIDS patients involving cross-resistance to amphotericin. Lancet. 348:1996;1523-1524.
25. Miyazaki Y., Geber A., Miyazaki H. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene. 236:1999;43-51.
26. Vanden Bossche H., Marichal P., Le Jeune L., Coene M. C., Gorrens J., Cools W. Effects of itraconazole on cytochrome P450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids inCryptococcus neoformans. Antimicrob Agents Chemother. 37:1993;2101-2105.
27. Wheat J., Marichal P., Vanden Bossche H., Le Monte A., Connolly P. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother. 41:1997;410-414.
28. Lamb D. C., Corran A., Baldwin B. C., Kwon-Chung K. J., Kelly S. L. Resistant sterol 14α-demethylase associated with clinical failure during fluconazole chemotherapy ofCryptococcus neoformans in AIDS patients. FEBS Lett. 368:1995;326-330.
29. Nes D. W., Janssen G. G., Cromley F. G., Kalinowska M., Akihisa T. The structural requirements of sterols for membrane function in Saccharomyces cerevisiae. Arch Biochem Biophys. 300:1993;724-733.
30. Joseph-Horne T., Loeffler R. S. T., Hollomon D., Kelly S. L. Cross resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother. 39:1995;1526-1529.
31. Lamb D. C., Kelly D. E., Waterman M. R., Stromstadt M., Rozman D., Kelly S. L. Characterisitics of the heterologously expressed human lanosterol 14α-demethylase (P45014DM, CYP51) and inhibition of the purified human and Candida albicans P45014DM with azole antifungal agents. Yeast. 15:1999;755-763.
32. White T. C. Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance inCandida albicans isolates from an HIV-infected patient. Antimicrob Agents Chemother. 41:1997;1482-1487.
33. Kenna S., Bligh H. F. J., Watson P. F., Kelly S. L. Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J Med Vet Mycol. 27:1989;397-406.
34. Marichal P., VandenBossche H., Odds F. C. Molecular-biological characterization of an azoleresistant Candida glabrata isolate. Antimicrob Agents Chemother. 41:1997;2229-2237.
35. Perepnikhatka V., Fischer F. J., Niimi M. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bact. 181:1999;4041-4049.
36. Watson P. F., Rose M. E., Kelly S. L. Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. J Med Vet Mycol. 26:1988;153-162.
37. Aoyama Y., Yoshida Y., Hata S. Altered cytochrome P450 in a yeast mutant blocked in demethylating C32 of lanosterol. J Biol Chem. 258:1983;9040-9042.
38. Kelly S. L., Lamb D. C., Corran A., Baldwin B. C., Kelly D. E. Mode of action and resistance to azole antifungals is associated with the formation of 14α-methylergosta - 8,24(28)-dien-3β, 6α-diol. Biochem Biophys Res Commun. 207:1995;910-915.
39. 5,6-desaturase in azole antifungal mode of action and resistance. Pestic Sci. 46:1996;294-298.
40. Shimokawa O., Kato Y., Kawano K., Nakayama H. Accumulation of 14α-methylergosta - 8, 24(28)-dien-3β, 6α-diol. in 14α-demethylation mutants ofCandida albicans : genetic evidence for the involvement of 5-desaturase. Biochem Biophys Acta. 1003:1989;15-19.
41. Vanden Bossche H., Marichal P. P., Gorrens J. Mode of action of antifungals of use in immunocompromised patients. Focus on Candida glabrata andHistoplama capsalatum. Vanden Bossche H., Mackenzie D. W. R., Cauenberg G., VanCutsum J., Drouhet E., Dupont B. Mycoses in AIDS Patients. 1990;223-243 Plenum
42. Gachotte D., Pierson C. A., Lees N. D., Barbuch R., Koegel C., Bard M. Yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci USA. 94:1997;11173-11178.
43. 5,6-desaturase as a cause of azole resistance in Ustilago maydis. FEMS Lett. 127:1995;29-34.
44. Nolte F. S., Parkinson T., Falconer D. J. Isolation and characterisation of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukaemia. Antimicrob Agents Chemother. 44:1997;196-199.
45. Howell S. A., Mallet A. I., Noble W. C. A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains. J Appl Bacteriol. 69:1990;692-696.
46. Geber A., Hitchcock C. A., Swartz J. E. Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition and antifungal susceptibility. Antimicrob Agents Chemother. 39:1995;2708-2717.
47. Marichal P., Gorrens J., Laurijssens L. Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates. Antimicrob Agents Chemother. 43:1999;2663-2670.
48. Sanglard D., Kuchler K., Ischer F., Pagani J-L., Monod M., Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 39:1995;2378-2386.
49. Venkateswarlu K., Denning D. W., Manning N. J., Kelly S. L. Resistance of fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Lett. 131:1995;337-341.
50. Venkateswarlu K., Denning D. W., Manning N. J., Kelly S. L. Reduced accumulation of drug in Candida krusei accounting for itraconazole resistance. Antimicrob Agents Chemother. 40:1996;2443-2446.
51. Orozco A. S., Higginbotham L. M., Hitchcock C. A. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 42:1998;2645-2649.
52. Ballard S. A., Ellis S. W., Kelly S. L., Troke P. F. A novel method for studying ergosterol biosynthesis by cell-free preparation of Aspergillus fumigatus and its inhibition by azole antifungal agents. J Med Vet Mycol. 28:1990;335-344.
53. Joseph-Horne T., Manning N., Hollomon D., Kelly S. L. Investigation of the sterol composition and azole resistance in a field isolate of Septoria tritici. App Enviro Microbiol. 62:1996;184-190.
54. De Waard M. A., Gieskes S. A. Characterisation of fenarimol resistant mutants of Aspergillus nidulans. Netherl J Plant Path. 83:1977;177-188.
55. Balzi E., Wang M., Leterme S., Van Dyck L., Goffeau A. PDR5, a novel yeast multidrug resistance conferrinng transporter controlled by the transcription regulator PDR1. J Biol Chem. 269:1994;2206-2214.
56. Fling M. E., Kopf J., Tamarkin A., Gorman J. A., Smith H. A., Koltin Y. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet. 227:1991;318-329.
57. Alarco A-M., Balan I., Talibi D., Mainville N., Raymond M. AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. J Biol Chem. 272:1997;19304-19313.
58. Marger M. D., Saier M. H. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends in Biomedical Sciences. 18:1993;13-20.
59. Bard M., Lees N. D., Barbuch R. J., Sanglard D. Characterisation of a cytochrome P450 deficient mutant of Candida albicans. Biochem Biophys Res Commun. 147:1987;794-800.
60. Vanden Bossche H., Marichal P., Gorrens J., Bellens D., Moereels H., Jannssen P. A. J. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans. 18:1990;56-59.
61. Lamb D. C., Manning N. J., Kelly D. E., Kelly S. L. Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363. FEMS Lett. 147:1997;189-193.
62. Joseph-Horne T., Hollomon D., Loeffler R. S. T., Kelly S. L. Altered P450 activity associated with direct selection for fungal azole resistance. FEBS Lett. 74:1995;174-178.
63. Lamb D. C., Kelly D. E., Schunck W. H. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem. 272:1997;5682-5688.
64. Kelly S. L. Fungal P450 with reference to azole mode of action and resistance. Proceedings of the 3rd International Symposium on P450 Biodiversity. Woods Hole, USA, 1995.
65. Loeffler J., Kelly S. L., Hebart H., Schumacher U., Lass-Florl C., Einsele H. Molecular analysis of CYP51 from fluconazole-resistant Candida albicans strains. FEMS Lett. 151:1997;263-268.
66. White T. C. The presence of an R367K amino acid substitution and loss of allelic variation correlate with an azole-resitant lanosterol demethylase in Candida albicans. Antimicrob Ag.ents Chemother. 41:1997;1488-1494.
67. Franz R., Kelly S. L., Lamb D. C., Kelly D. E., Ruhnke M., Morschhüauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother. 42:1998;3065-3072.
68. Kelly S. L., Lamb D. C., Loeffler J., Einsele H., Kelly D. E. The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun. 262:1999;174-179.
69. Lamb D. C., Kelly D. E., White T. C., Kelly S. L. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Antimicrob Agents Chemother. 2000.
70. Delye C., Laigret F., Corio-Costet M-F. A mutation in the 14α-demethylase gene of Uncinula necator that correlates with resistance to a sterol biosynthesis inhibitor. App Env Microbiol. 63:1997;2966-2970.
71. Sanglard D., Ischer F., Koymans L., Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha- demethylase (CYP51A1) from azole-resistantCandida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 42:1998;241-253.
72. Asai K., Tsuchimori N., Okonogi K., Perfect J. R., Gotoh O., Yoshida Y. Formation of azoleresistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother. 43:1998;1163-1169.
73. Lamb D. C., Kelly D. E., Venkateswarlu K., Schunck W-H., Kelly S. L. Generation of a complete soluble and catalytically active sterol 14α-demethylase/reductase complex. Biochemistry. 38:1999;8733-8738.
74. Venkateswarlu K., Lamb D. C., Kelly D. E., Manning N. J., Kelly S. L. The N-terminal domain of yeast NADPH-cytochrome P450 reductase is not required in sterol biosynthesis. J Biol Chem. 273:1998;4492-4496.
75. Lamb D. C., Kelly D. E., Baldwin B. C. Differential inhibition of Candida albicans CYP51 by stereoisomers of azole antifungals. FEMS Lett. 149:1997;25-30.
76. Hasemann C. A., Kurumbail R. G., Boddupalli S. S., Peterson J. A., Deisenhofer J. Structure and function of cytochromes P450- a comparative analysis of 3 crystal structures. Structure. 3:1995;41-62.
77. Cole S. T. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:1998;537-544.
78. Bellamine A., Mangla A. T., Nes W. D., Waterman M. R. Characterization and catalytic properties of the sterol 14 alpha-demethylase from Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 96:1999;8937-8942.
79. Lamb D. C., Kelly D. E., Manning N. J., Kelly S. L. A sterol biosynthetic pathway in Mycobacterium. FEBS Lett. 437:1998;142-144.
80. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Inf Dis. 9:1987;57-63.
81. Giaever G., Shoemaker D. D., Jones T. W. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nature Gen. 21:1999;278-283.
82. Kenna S., Bligh H. F. J., Watson P. F., Kelly S. L. Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J Med Vet Mycol. 27:1989;397-406.
83. Rine J., Hansen W., Hardeman E., Davis R. W. Targeted selection of recombinant clones through gene dosage effects. Proc Nat Acad Sci USA. 80:1983;6750-6754.